As cancers that have lost MAP3K1 or MAP2K4 fail to activate JNK, loss-of-function mutations in MAP3K1 or MAP2K4 confer sensitivity to MEK inhibition, as shown in cell cultures and patient-derived xenograft (PDX) models [200]. The gene discussed is MAP2K4; the disease is cancer.